Is monitoring mean platelet volume necessary in breast cancer patients?

Taskaynatan H., ALACACIOĞLU A., KÜÇÜKZEYBEK Y., Varol U., Yildiz Y., Salman T., ...More

OPEN MEDICINE, vol.13, no.1, pp.450-455, 2018 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 13 Issue: 1
  • Publication Date: 2018
  • Doi Number: 10.1515/med-2018-0067
  • Journal Name: OPEN MEDICINE
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.450-455
  • Keywords: Breast cancer, Tamoxifen, Aromatase inhibitors, Mean platelet volume, Side effect, ADJUVANT ENDOCRINE THERAPY, CORONARY-ARTERY DISEASE, VENOUS THROMBOEMBOLISM, MYOCARDIAL-INFARCTION, AROMATASE INHIBITORS, ADVERSE EVENTS, RISK-FACTOR, TAMOXIFEN, ACTIVATION, METAANALYSIS
  • Dokuz Eylül University Affiliated: Yes

Abstract

Background: Mean platelet volume (MPV) is a parameter that increases during thrombotic and cardiovascular events. Tamoxifen (Tmx) and aromatase inhibitors (AIs), which are adjuvant endocrine therapies, may cause serious side effects, such as vascular thrombosis. The present study investigated the changes in MPV values of breast cancer patients receiving long-term adjuvant hormone therapy and the relationship of MPV with adverse effects of hormonotherapy.